ReviewWorld journal of clinical oncology2019
Malignant hepatic vascular tumors in adults: Characteristics, diagnostic difficulties and current management.
Review in World journal of clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 38 citations in OpenAlex.
- Primary hepatic angiosarcoma misdiagnosed as hemangioma despite repeated negative biopsies and sclerotherapy: A diagnostic pitfall.Radiology case reports · 2026Article
- Primary Hepatic Perivascular Epithelioid Cell Tumors: From Diagnosis to Treatment.Life (Basel, Switzerland) · 2026Review
- Article
- A Rare Case of Solitary Primary and Recurrent Hepatic Epithelioid Hemangioendothelioma Undergoing Repeat Liver Resections.Surgical case reports · 2025Article
- Hepatic perivascular epithelioid cell tumors: The importance of preoperative diagnosis.World journal of gastroenterology · 2024Review
- Primary hepatic angiosarcoma: a systematic review.Annals of medicine and surgery (2012) · 2024Review
- Vascular tumors of the liver: A brief review.Annals of hepato-biliary-pancreatic surgery · 2023Review
- LncASAP1-IT1 promotes hepatocellular carcinoma progression through the regulation of the miR-1294/TGFBR1 pathwayJournal of gastrointestinal oncology · 2023Article
- Article
- Multifocal hepatic small vessel neoplasm with spleen dissemination.BMJ case reports · 2022Article
- Advanced epithelioid hemangioendothelioma of the liver: could lenvatinib offer a bridge treatment to liver transplantation?Therapeutic advances in medical oncology · 2022Article
- Treatment and Prognosis of Hepatic Epithelioid Hemangioendothelioma: A SEER Database Analysis.World journal of surgery · 2021Article
- Liver transplantation in malignant disease.World journal of clinical oncology · 2021Review
- Clinical characteristics of primary hepatic angiosarcoma outcomes: a SEER database analysis.Translational cancer research · 2021Article
- Liver transplantation for rare liver diseases and rare indications for liver transplant.Translational gastroenterology and hepatology · 2021Review
- Laparoscopic repeat liver resection for hepatic epithelioid hemangioendothelioma.Surgical case reports · 2020Article
- Hepatic epithelioid hemangioendothelioma: case series of a rare vascular tumor mimicking metastases.Diagnostic pathology · 2020Article
- LncRNA BCAR4 promotes liver cancer progression by upregulating ANAPC11 expression through sponging miR‑1261.International journal of molecular medicine · 2020Article
- Hepatic Hemangioendothelioma: An update.World journal of gastrointestinal oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant vascular tumors of the liver include rare primary hepatic mesenchymal tumors developed in the background of a normal liver parenchyma. Most of them are detected incidentally by the increased use of performing imaging techniques. Their diagnosis is challenging, involving clinical and imaging criteria, with final confirmation by histology and immunohistochemistry. Surgery represents the mainstay of treatment. Liver transplantation (LT) has improved substantially the prognosis of hepatic epithelioid hemangioendothelioma (HEHE), with 5-year patient survival rates of up to 81%, based on the European Liver Intestine Transplantation Association-European Liver Transplant Registry study. Unfortunately, the results of surgery and LT are dismal in cases of hepatic angiosarcoma (HAS). Due to the disappointing results of very short survival periods of approximately 6-7 mo after LT, because of tumor recurrence and rapid progression of the disease, HAS is considered an absolute contraindication to LT. Recurrences after surgical resection are high in cases of HEHE and invariably present in cases of HAS. The discovery of reliable prognostic markers and the elaboration of prognostic scores following LT are needed to provide the best therapeutic choice for each patient. Studies on a few patients have demonstrated the stabilization of the disease in a proportion of patients with hepatic vascular tumors using novel targeted antiangiogenic agents, cytokines or immunotherapy. These new approaches, alone or in combination with other therapeutic modalities, such as surgery and classical chemotherapy, need further investigation to assess their role in prolonging patient survival. Personalized therapeutic algorithms according to the histopathological features, behavior, molecular biology and genetics of the tumors should be elaborated in the near future for the management of patients diagnosed with primary malignant vascular tumors of the liver.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.